Compare
Quanterix Corp vs Cytek Biosciences, Inc. vs 908 Devices Inc. vs Rapid Micro Biosystems, Inc.
| Latest fiscal year | Quanterix Corp QTRX | Cytek Biosciences, Inc. CTKB | 908 Devices Inc. MASS | Rapid Micro Biosystems, Inc. RPID |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $138.90M | $201.49M | $56.20M | $33.59M |
| Revenue growth (YoY) | +1.1% | +0.5% | +17.7% | +19.7% |
| Gross margin | 46.8% | 51.8% | 50.6% | n/a |
| Operating margin | -90.4% | -20.0% | -70.1% | -141.1% |
| Net margin | -77.1% | -33.0% | 34.7% | -140.3% |
| Net income | -$107.15M | -$66.54M | $19.49M | -$47.12M |
| EPS (Diluted) | -$2.51 | n/a | $0.54 | -$1.05 |
| Operating cash flow | -$77.24M | -$4.69M | -$23.69M | -$31.06M |
| Free cash flow | -$79.85M | -$8.77M | -$24.64M | -$31.91M |
| Cash & equivalents | $29.84M | $90.85M | $70.52M | $20.03M |
| Total assets | $418.77M | $461.54M | $190.07M | $74.85M |
| Total liabilities | $123.04M | $119.80M | $46.37M | $41.65M |
| Shareholders' equity | $295.73M | $341.74M | $143.70M | $33.21M |
| Return on year-end equity | -36.2% | -19.5% | 13.6% | -141.9% |
| Shares outstanding | 46.74M | 128.55M | 36.32M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Quanterix Corp | Cytek Biosciences, Inc. | 908 Devices Inc. | Rapid Micro Biosystems, Inc. |
|---|---|---|---|---|
| Latest | $138.90M Ended 2025-12-31 | $201.49M Ended 2025-12-31 | $56.20M Ended 2025-12-31 | $33.59M Ended 2025-12-31 |
| 1 year earlier | $137.42M Ended 2024-12-31 | $200.45M Ended 2024-12-31 | $47.75M Ended 2024-12-31 | $28.05M Ended 2024-12-31 |
| 2 years earlier | $122.37M Ended 2023-12-31 | $193.01M Ended 2023-12-31 | $50.23M Ended 2023-12-31 | $22.52M Ended 2023-12-31 |
| 3 years earlier | $105.52M Ended 2022-12-31 | $164.04M Ended 2022-12-31 | $46.85M Ended 2022-12-31 | $17.13M Ended 2022-12-31 |
| 4 years earlier | $110.56M Ended 2021-12-31 | $127.95M Ended 2021-12-31 | $42.21M Ended 2021-12-31 | $23.23M Ended 2021-12-31 |